Magnetar Financial’s European Biotech Acquisition Corp. Units EBACU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-158,504
Closed -$1.55K 1842
2022
Q2
$1.55K Sell
158,504
-88,596
-36% -$872K 0.02% 811
2022
Q1
$2.43M Sell
247,100
-7,600
-3% -$75.1K 0.03% 629
2021
Q4
$2.52M Sell
254,700
-6,500
-2% -$64.4K 0.03% 626
2021
Q3
$2.6M Hold
261,200
0.03% 568
2021
Q2
$2.61K Buy
261,200
+5,800
+2% +$58K 0.02% 544
2021
Q1
$2.57M Buy
+255,400
New +$2.55M 0.02% 524

Other funds holding EBACU

Magnetar Financial's EBACU Position: Q3 2022 in Review

Magnetar Financial sold out of European Biotech Acquisition Corp. Units (EBACU) in Q3 2022, closing a stake of 158,504 shares — an estimated $1.55K sold.

Magnetar Financial first reported a position in EBACU in Q1 2021 and held it in 6 quarters. The position peaked at $2.6M in Q3 2021. 18 funds tracked by Wall St. Rank hold EBACU as of Q3 2022.

  • Magnetar Financial reported no remaining European Biotech Acquisition Corp. Units position as of Q3 2022 after selling out during the quarter.
  • Magnetar Financial sold 158,504 European Biotech Acquisition Corp. Units shares in Q3 2022, an estimated $1.55K.
  • Magnetar Financial first reported a position in European Biotech Acquisition Corp. Units in Q1 2021 and held it in 6 quarters.
  • Magnetar Financial's European Biotech Acquisition Corp. Units position peaked at $2.6M in Q3 2021.
  • 18 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Units as of Q3 2022.

Based on Magnetar Financial's 13F filing for Q3 2022, filed 14 Nov 2022.